As a tyrosine kinase inhibitor, apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells [33]. The gene discussed is SLC2A4; the disease is ovarian carcinoma.